apceth Biopharma

21 articles about apceth Biopharma

• Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with bluebird bio

  5/11/2020

  Hitachi Chemical Advanced Therapeutics Solutions, LLC and apceth Biopharma GmbH, both subsidiaries of Hitachi Chemical Co., Ltd. announced that they have expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including:.

• 

  BioSpace Global Roundup, Jan. 16

  1/16/2020

  Companies from across the globe provide updates to their business and pipeline.

• apceth Starts Commercial Manufacturing of Zynteglo™ ▼, bluebird bio’s Gene Therapy for Transfusion-Dependent β-Thalassemia

  1/13/2020

  apceth Biopharma GmbH, a subsidiary of Hitachi Chemical Co., Ltd. and a leading company for the manufacturing of cell and gene therapeutics, starts the commercial manufacturing of Zynteglo™ ▼, a product of bluebird bio, Inc.

• Hitachi Chemical Co. Ltd. to Acquire apceth Biopharma GmbH, Expanding Global Footprint of its Cell and Gene Therapy Contract Development and Manufacturing Services

  1/31/2019

  apceth Biopharma manufactures cell and gene therapy products for American and European clients through two manufacturing sites in Munich, Germany, certified for GMP manufacture since 2010

• apceth Biopharma Presents Positive Data Demonstrating Efficacy of  apceth-201 in Preclinial Models of Acute GvHD

  10/19/2018

  apceth Biopharma GmbH announced today positive results for apceth-201 in mouse models for acute graft-versus-host disease (aGvHD).

• apceth to Manufacture First Potential One-Time Gene Therapy for Transfusion-Dependent β-Thalassemia

  10/5/2018

  pceth Biopharma GmbH congratulates its partner bluebird bio on the acceptance and validation of its market authorization application by the European Medicines Agency (EMA).

• apceth Biopharma Appoints a New Supervisory Board

  11/9/2017

  Manfred Ruediger, Chairman, is a seasoned senior executive with over 20 years’ experience in leading biotech companies both at the management and board levels.

• DCPrime and apceth Biopharma GmbH Announce Manufacturing Partnership

  10/20/2017

  DCPrime BV and apceth Biopharma GmbH, an established contract manufacturing organization in the field of gene and cell therapy, report today that they have entered into a strategic manufacturing agreement.

• apceth Biopharma Appoints Dusan Kosijer As Chief Financial Officer

  5/31/2017

• bluebird bio And apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement

  12/15/2016

• Cynata Enters License Option Agreement With Apceth GmbH

  5/9/2016

• Apceth GmbH And University of Cologne To Join Forces On Combination Cellular Immunotherapies For Cancer

  7/10/2015

• Apceth GmbH Expands Further Its GMP Manufacturing Business

  6/22/2015

• Apceth GmbH Names Ulrike Verzetnitsch As Chief Technical Officer

  4/23/2015

• Apceth GmbH Initiates Phase II Clinical Trial For Pioneering Engineered Cell Therapy To Treat Gastrointestinal Cancer

  3/26/2015

• Apceth GmbH 's Ground-Breaking First-In-Man, First-In-Class Clinical Trial In Oncology With Genetically Modified Mesenchymal Stem Cells Is Now Enrolling

  1/23/2014

• Apceth GmbH Names Dr Stefanos Theoharis Chief Business Officer

  9/5/2013

• As the First Biopharmaceutical Company Worldwide, Apceth GmbH Receives Approval for a Clinical Trial With Genetically Modified Adult Mesenchymal Stem Cells for the Treatment of Cancer

  6/13/2013

• Apceth GmbH Received the Second Round of Funding for Its Innovative Stem Cell-Based Cancer Therapeutic as Part of the m4 Initiative of the Munich Biotech Cluster

  2/4/2013

• Apceth GmbH and Indivumed GmbH to Develop Biomarker Platform for Targeted Cellular Therapies

  2/22/2012